Huayunuo approval positions China at forefront of viral hepatitis innovation, says GlobalData
Huahui Health has recently secured conditional approval from China for Huayunuo (Libevitug Injection), marking it as the first domestically developed monoclonal antibody (mAb) drug for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.